Targeting of USP8 reduces survival pathway activation in ovarian carcinoma preclinical models of cisplatin resistance 90, offering novel opportunities for drug development in this disease and in many neoplastic diseases with a key role for EGFR activation including for example lung cancer in which down-regulation of the HER family receptor phosphorylation was observed following molecular and pharmacological inhibition of USP8 91. Here, USP8 is linked to ovarian carcinoma.